

## Accepted Manuscript

Stockout Risk of Production-Inventory Systems with Compound Poisson Demands

Jasmine (Ai-Chih) Chang, Haibing Lu, Jim (Junmin) Shi

PII: S0305-0483(18)30248-2  
DOI: [10.1016/j.omega.2018.03.001](https://doi.org/10.1016/j.omega.2018.03.001)  
Reference: OME 1884



To appear in: *Omega*

Received date: 21 February 2016  
Revised date: 4 March 2018  
Accepted date: 5 March 2018

Please cite this article as: Jasmine (Ai-Chih) Chang, Haibing Lu, Jim (Junmin) Shi, Stockout Risk of Production-Inventory Systems with Compound Poisson Demands, *Omega* (2018), doi: [10.1016/j.omega.2018.03.001](https://doi.org/10.1016/j.omega.2018.03.001)

This is a PDF file of an unedited manuscript that has been accepted for publication. As a service to our customers we are providing this early version of the manuscript. The manuscript will undergo copyediting, typesetting, and review of the resulting proof before it is published in its final form. Please note that during the production process errors may be discovered which could affect the content, and all legal disclaimers that apply to the journal pertain.

# Stockout Risk of Production-Inventory Systems with Compound Poisson Demands

Jasmine (Ai-Chih) Chang

Dept. of Supply Chain Management, Rutgers Business School - Newark and New Brunswick  
Rutgers, the State University of New Jersey  
aichih@rutgers.edu

Haibing Lu

Dept. of Operations Management and Information Systems  
Santa Clara University  
hlu@scu.edu

Jim (Junmin) Shi

Tuchman School of Management, New Jersey Institute of Technology  
Rutgers Business School - Newark and New Brunswick, Rutgers, the State University of New Jersey  
Junmin.Shi@njit.edu

Production-inventory systems with continuous production or continuous manufacturing have been implemented in a variety of manufacturing contexts. Most recently, the Commissioner of the FDA has called on drug and biological product manufacturers to begin switching from batch manufacturing processes to continuous production. Motivated by prevailing applications and the emerging and promising landscape in the healthcare and pharmaceutical industries, this paper studies a continuous-review production-inventory system with a constant production rate and compound Poisson demands, in which the cost of the system is assessed via inventory holding, stockout penalty and production costs. For any initial inventory, we derive a closed-form expression for the expected discounted cost function until stockout occurrence. We systemically quantify the stockout risk on four different dimensions (i.e., *time*, *volume*, *frequency* and *percentage*) and derive explicit expressions for each type of risk metric. The objective is to derive the production rate that minimizes the expected discounted system cost subject to a given risk tolerance level on stockouts. With the aid of the derived explicit forms of stockout risk and the cost function, we develop a computationally-efficient algorithm for the optimal solution. Extensive numerical studies are conducted to illustrate our results with rich insights. Numerically, we show that it is outrageously costly to reduce stockout risk, especially when this risk is relatively low; the value of risk is more sensitive to the stockout risk level if the demand distribution has a higher volatility.

*Key words:* Pharmaceutical manufacturing, drug shortage, production-inventory systems, continuous manufacturing, stockout risk, risk metrics.

*History:* Submitted on Feb. 16, 2016; the Latest Revision is as of Mar. 2018

## 1. Introduction

Production-inventory systems with continuous production or continuous manufacturing have been commonly implemented in a variety of manufacturing contexts, such as oil refining, metal smelting, natural gas processing, steel refining, chemical production, carpet and textile manufacturing, and many others; cf. BioProcess Online, 2016. In the context of pharmaceuticals, many pharmaceutical manufacturers are already converting their processes to adopt continuous production, e.g., continuous production of cell-free proteins, nanostructured particles and exosomes; cf. Membrane Separation Technology News (1997), van Ommen *et al.* (2015) and Whitford *et al.* (2015). Most recently, the Commissioner of the FDA has called on drugs and biological product manufacturers to begin switching from batch manufacturing processes to continuous production; cf. Brennan (2015). The development and implementation of such manufacturing technology based on continuous production can overcome many chronic limitations (e.g., lowering cost and improving quality). Accordingly, *Integrated Continuous Manufacturing* (ICM) will be the ultimate goal for this industry.

متن کامل مقاله

دریافت فوری ←

**ISI**Articles

مرجع مقالات تخصصی ایران

- ✓ امکان دانلود نسخه تمام متن مقالات انگلیسی
- ✓ امکان دانلود نسخه ترجمه شده مقالات
- ✓ پذیرش سفارش ترجمه تخصصی
- ✓ امکان جستجو در آرشیو جامعی از صدها موضوع و هزاران مقاله
- ✓ امکان دانلود رایگان ۲ صفحه اول هر مقاله
- ✓ امکان پرداخت اینترنتی با کلیه کارت های عضو شتاب
- ✓ دانلود فوری مقاله پس از پرداخت آنلاین
- ✓ پشتیبانی کامل خرید با بهره مندی از سیستم هوشمند رهگیری سفارشات